Free tool
FAERS Monitor: Simponi
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 125289 or its brand name (Simponi, Golimumab). Reports on generic versions are filed under their own applications.
Reports
82,613
Serious
63,267
77% of reports
Hospitalization
20,569
Death reported
6,620
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective20,904
- rheumatoid arthritis14,421
- pain13,603
- fatigue11,495
- off label use10,334
- joint swelling9,990
- arthralgia9,925
- rash9,542
- alopecia9,499
- drug intolerance9,039
- abdominal discomfort8,929
- swelling8,729
- systemic lupus erythematosus8,670
- contraindicated product administered8,526
- pemphigus8,418
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2006 | 1 |
| 2009 | 162 |
| 2010 | 466 |
| 2011 | 926 |
| 2012 | 1,390 |
| 2013 | 1,783 |
| 2014 | 1,502 |
| 2015 | 5,521 |
| 2016 | 5,121 |
| 2017 | 5,146 |
| 2018 | 6,113 |
| 2019 | 6,581 |
| 2020 | 9,069 |
| 2021 | 7,170 |
| 2022 | 6,970 |
| 2023 | 6,296 |
| 2024 | 7,865 |
| 2025 | 6,880 |
| 2026 | 3,651 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,971,546 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| pemphigusSignal | 8,418 | 521.7 | 502.9 | 1,432,661 |
| contraindicated product administeredSignal | 8,526 | 99.4 | 97.0 | 597,453 |
| systemic lupus erythematosusSignal | 8,670 | 81.9 | 80.1 | 524,874 |
| rheumatoid arthritisSignal | 14,421 | 36.9 | 36.3 | 442,053 |
| drug intoleranceSignal | 9,039 | 26.2 | 25.6 | 199,302 |
| swellingSignal | 8,729 | 26.1 | 25.5 | 191,769 |
| joint swellingSignal | 9,990 | 22.9 | 22.4 | 192,826 |
| abdominal discomfortSignal | 8,929 | 14.3 | 14.0 | 105,038 |
| alopeciaSignal | 9,499 | 12.9 | 12.6 | 100,063 |
| arthralgiaSignal | 9,925 | 6.2 | 6.1 | 43,114 |
| painSignal | 13,603 | 5.7 | 5.7 | 53,667 |
| rashSignal | 9,542 | 5.7 | 5.6 | 36,705 |
| drug ineffectiveSignal | 20,904 | 4.1 | 4.0 | 51,176 |
| fatigueSignal | 11,495 | 3.8 | 3.7 | 24,265 |
| off label useSignal | 10,334 | 3.0 | 3.0 | 14,477 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.